Evidence map›Paper›PMID 31827636›Full record

ArticleDisease markers2019

Whole-Genome Sequencing Identifies the Egl Nine Homologue 3 (egln3/phd3) and Protein Phosphatase 1 Regulatory Inhibitor Subunit 2 (PPP1R2P1) Associated with High-Altitude Polycythemia in Tibetans at High Altitude.

Luobu Gesang, Lamu Gusang, Ciren Dawa, Gawa Gesang, Kang Li

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Luobu GesangHigh Altitude Medical Research Institute of Tibet, Lhasa 850000, China.
Lamu GusangHigh Altitude Medical Research Institute of Tibet, Lhasa 850000, China.
Ciren DawaHigh Altitude Medical Research Institute of Tibet, Lhasa 850000, China.
Gawa GesangHigh Altitude Medical Research Institute of Tibet, Lhasa 850000, China.
Kang LiHigh Altitude Medical Research Institute of Tibet, Lhasa 850000, China.ORCID https://orcid.org/0000-0002-2867-0562
Tibet Autonomous Region People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe hypoxic conditions at high altitudes are great threats to survival, causing pressure for adaptation. More and more high-altitude denizens are not adapted with the condition known as high-altitude polycythemia (HAPC) that featured excessive erythrocytosis. As a high-altitude sickness, the etiology of HAPC is still unclear.

methodsIn this study, we reported the whole-genome sequencing-based study of 10 native Tibetans with HAPC and 10 control subjects followed by genotyping of selected 21 variants from discovered single nucleotide variants (SNVs) in an independent cohort (232 cases and 266 controls).

resultsWe discovered the egl nine homologue 3 (egln3/phd3) (14q13.1, rs1346902,

conclusionsOur genome sequencing conducted in Tibetan HAPC patients identified egln3/phd3 and PPP1R2P1 associated with HAPC.

Indexed as

Polymorphism, Single NucleotideAdultAgedAltitude SicknessBiomarkersCase-Control StudiesFemaleFollow-Up StudiesGenome, HumanGenotypeHumansHypoxiaHypoxia-Inducible Factor-Proline DioxygenasesMaleMiddle AgedPolycythemiaBiomarkersEGLN3 protein, humanHypoxia-Inducible Factor-Proline DioxygenasesProtein Phosphatase 1

Identifiers

PMID31827636
PMCPMC6881591
OpenAlexW2985431948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.